Solid Malignancies Among Etanercept-Treated Patients With Granulomatosis With Polyangiitis (Wegener's) Long-Term Followup of a Multicenter Longitudinal Cohort

Simple item page
dc.contributor.authorSilva, Francisco
dc.contributor.authorSeo, Philip
dc.contributor.authorSchroeder, Darrell R.
dc.contributor.authorStone, John H.
dc.contributor.authorMerkel, Peter A.
dc.contributor.authorHoffman, Gary S.
dc.contributor.authorSpiera, Robert
dc.contributor.authorSebastian, Jodi K.
dc.contributor.authorDavis, John C., Jr.
dc.contributor.authorSt Clair, E. William
dc.contributor.authorAllen, Nancy B.
dc.contributor.authorMcCune, W. Joseph
dc.contributor.authorYtterberg, Steven R.
dc.contributor.authorSpecks, Ulrich
dc.contributor.authorWegener's Granulomatosis
dc.date.accessioned2024-01-10T13:43:36Z
dc.date.available2024-01-10T13:43:36Z
dc.date.issued2011
dc.description.abstractObjective. An association between therapeutic inhibition of tumor necrosis factor (TNF) and solid malignancies was observed during the Wegener's Granulomatosis Etanercept Trial (WGET), which included 180 patients with granulomatosis with polyangiitis (Wegener's) (GPA). The present study was conducted to determine the malignancy risk beyond the time of exposure to study therapy.
dc.description.abstractMethods. The occurrence and type of solid malignancies were ascertained using a standardized data form. Data collected included vital status, histologic findings, and therapeutic interventions. The Surveillance, Epidemiology, and End-
dc.description.abstractResults database was used to estimate a standardized incidence rate (SIR) for solid malignancies. Results. Post-trial followup data were available for 153 patients (85% of the original cohort), with a median followup time of 43 months. Fifty percent of these patients had received etanercept. There were no differences in demographic characteristics between the etanercept and placebo groups. Thirteen new solid malignancies were detected, 8 in the etanercept group and 5 in the placebo group. Compared to the general population, the risk of solid malignancies in the etanercept group was increased (SIR 3.92 [95% confidence interval 1.69-7.72]), but was not different from the risk in the placebo group compared to the general population (SIR 2.89 [95% confidence interval 0.94-6.73]). All solid malignancies occurred in patients who had been exposed to cyclophosphamide. The overall duration of disease and a history of malignancy before trial enrollment were associated with the development of malignancy during post-trial followup.
dc.description.abstractConclusion. The incidence of solid malignancy remained increased during long-term followup of the WGET cohort. However, this could not be attributed solely to etanercept exposure during the trial. Anti-TNF therapy with etanercept appears to further increase the risk of malignancy observed in patients with GPA treated with cytotoxic agents and should be avoided in these patients.
dc.description.funderNIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases)
dc.description.funderFDA (Office of Orphan Products Development)
dc.description.funderVasculitis Clinical Research Consortium through the NIH (National Center for Research Resources and National Institute of Arthritis and Musculoskeletal and Skin Diseases)
dc.description.funderMayo Foundation for Medical Education and Research
dc.description.funderVasculitis Clinical Research Consortium
dc.description.funderNATIONAL CENTER FOR RESEARCH RESOURCES
dc.description.funderNATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
dc.fechaingreso.objetodigital03-04-2024
dc.format.extent9 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1002/art.30394
dc.identifier.eissn1529-0131
dc.identifier.issn0004-3591
dc.identifier.pubmedidMEDLINE:21484770
dc.identifier.urihttps://doi.org/10.1002/art.30394
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78694
dc.identifier.wosidWOS:000293840200039
dc.information.autorucMedicina;Silva F ;S/I;7423
dc.issue.numero8
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final2503
dc.pagina.inicio2495
dc.publisherWILEY
dc.revistaARTHRITIS AND RHEUMATISM
dc.rightsacceso restringido
dc.subjectTUMOR-NECROSIS-FACTOR
dc.subjectSQUAMOUS-CELL CARCINOMA
dc.subjectPOPULATION-BASED COHORT
dc.subjectRHEUMATOID-ARTHRITIS
dc.subjectFACTOR-ALPHA
dc.subjectCANCER MORBIDITY
dc.subjectINCREASED RISK
dc.subjectLYMPHOMA
dc.subjectTHERAPY
dc.subjectDISEASE
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleSolid Malignancies Among Etanercept-Treated Patients With Granulomatosis With Polyangiitis (Wegener's) Long-Term Followup of a Multicenter Longitudinal Cohort
dc.typeartículo
dc.volumen63
sipa.codpersvinculados7423
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Solid Malignancies Among Etanercept-Treated Patients With Granulomatosis With Polyangiitis (Wegener's) Long-Term Followup of a Multicenter Longitudinal Cohort.pdf
Size:
3.36 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas